BioCryst Pharmaceuticals, Inc. (BCRX)
8.67
-0.03
(-0.34%)
USD |
NASDAQ |
Sep 18, 16:00
8.61
-0.06
(-0.69%)
After-Hours: 20:00
BioCryst Pharmaceuticals Price : 8.67 for Sept. 18, 2026
Price Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | 8.54 | 8.73 | 8.425 | 8.70 | 5.221M |
| Sep 16, 2026 | 8.15 | 8.45 | 8.11 | 8.43 | 5.860M |
| Sep 15, 2026 | 8.19 | 8.23 | 8.020 | 8.16 | 6.113M |
| Sep 14, 2026 | 8.17 | 8.38 | 8.095 | 8.23 | 5.097M |
| Sep 11, 2026 | 8.30 | 8.397 | 8.105 | 8.12 | 3.592M |
| Sep 10, 2026 | 8.34 | 8.46 | 8.045 | 8.29 | 9.001M |
| Sep 09, 2026 | 9.07 | 9.23 | 8.80 | 8.805 | 5.153M |
| Sep 08, 2026 | 9.122 | 9.40 | 8.96 | 9.065 | 9.688M |
| Sep 04, 2026 | 10.00 | 10.10 | 9.895 | 9.96 | 1.496M |
| Sep 03, 2026 | 10.15 | 10.22 | 9.935 | 10.09 | 1.974M |
| Sep 02, 2026 | 10.00 | 10.23 | 9.83 | 10.17 | 3.130M |
| Sep 01, 2026 | 9.72 | 9.955 | 9.63 | 9.92 | 3.367M |
| Aug 31, 2026 | 9.72 | 9.72 | 9.46 | 9.70 | 2.756M |
| Aug 28, 2026 | 9.822 | 9.96 | 9.72 | 9.82 | 2.703M |
| Aug 27, 2026 | 9.75 | 9.92 | 9.551 | 9.87 | 2.479M |
| Aug 26, 2026 | 9.77 | 9.90 | 9.71 | 9.83 | 1.859M |
| Aug 25, 2026 | 9.79 | 9.916 | 9.698 | 9.83 | 2.333M |
| Aug 24, 2026 | 9.50 | 9.755 | 9.48 | 9.68 | 2.010M |
| Aug 21, 2026 | 9.72 | 9.905 | 9.48 | 9.55 | 2.497M |
| Aug 20, 2026 | 9.92 | 9.988 | 9.595 | 9.66 | 2.329M |
| Aug 19, 2026 | 9.93 | 10.11 | 9.765 | 10.07 | 2.907M |
| Aug 18, 2026 | 9.89 | 9.94 | 9.545 | 9.70 | 2.122M |
| Aug 17, 2026 | 9.72 | 10.02 | 9.65 | 9.94 | 2.123M |
| Aug 14, 2026 | 9.68 | 9.800 | 9.46 | 9.74 | 3.821M |
| Aug 13, 2026 | 10.59 | 10.63 | 9.70 | 9.81 | 4.583M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Amgen, Inc. | 385.64 |
| Halozyme Therapeutics, Inc. | 112.65 |
| Neurocrine Biosciences, Inc. | 146.16 |
| Vertex Pharmaceuticals, Inc. | 508.26 |
| Agenus, Inc. | 7.855 |
Price Related Metrics
| PS Ratio | 2.181 |
| PEG Ratio | -0.0076 |
| Price to Free Cash Flow | 5.759 |
| Earnings Yield | -17.35% |
| Market Cap | 2.213B |
| PEGY Ratio | -0.0076 |
| Operating PE Ratio | 5.335 |
| Normalized PE Ratio | 15.53 |